Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 13.39 +1.90%
TRVI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.87B
- EPS (TTM)
- -$0.35
- Dividend yield
- None
- 52-week range
- 9.28 – 20.22
- Day range
- 12.84 – 13.53
- Volume / Avg
- 5.20M / 1.91M
- Beta
- —
- Shares outstanding
- 142.48M
52-week range
TRVI stock today
Trevi Therapeutics (TRVI) closed at $13.14 on Oct 7, down 0.30% (-$0.04), versus the S&P 500's 0.22% decline. Volume was 2.7x the average at 5.20M shares, a sign of unusually heavy trading. Shares are 35.0% below their 52-week high of $20.22, set on Jul 17, 2026 and 41.6% above the 52-week low of $9.28, in the middle of the past year's range.
TRVI is up 5.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 37.6%. Trevi Therapeutics has posted a net loss over the last twelve months (EPS of -$0.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Trevi Therapeutics
Company profileTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jennifer L. Good
- Headquarters
- New Haven, CT
- Employees
- 34
- IPO year
- 2019
- Website
- trevitherapeutics.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$28.18+114.46%
- Strong buy 2
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Trevi Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs TRVI |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs TRVI |
| GPCRStructure Therapeutics Inc. ADR | 26.68 | -2.88% | $1.90B | vs TRVI |
| ZYMEZymeworks Inc. | 26.53 | +3.43% | $1.90B | vs TRVI |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs TRVI |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs TRVI |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs TRVI |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs TRVI |
Indexes, lists and sector
Trevi Therapeutics stock FAQ
What is Trevi Therapeutics's stock price today?
TRVI last traded at $13.14 as of Oct 7, 4:00 PM EDT, down 0.30% on the day. Prices are delayed at least 15 minutes.
Who is Trevi Therapeutics's CEO?
Ms. Jennifer L. Good is the chief executive officer of Trevi Therapeutics Inc., which has about 34 employees.
What is the TRVI 52-week high?
The 52-week high for TRVI is $20.22 and the 52-week low is $9.28. The stock is currently 35.0% below its high.